Arbutus Biopharma (ABUS) Other Non-Current Assets (2010 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Other Non-Current Assets of $131000.0 for Q1 2026, up 285.29% year-on-year from $34000.0 in Q1 2025, and up 0.77% on a QoQ basis from $130000.0 in Q4 2025.
Arbutus Biopharma (ABUS) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Other Non-Current Assets for 13 consecutive years, with $131000.0 the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Assets rose 285.29% year-over-year to $131000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131000.0 (up 285.29% YoY) and the FY2025 annual result came in at $130000.0, up 282.35% from the prior year.
- Other Non-Current Assets rose to $131000.0 in Q1 2026 per ABUS's latest filing, from $130000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for ABUS reached as high as $190000.0 in Q1 2022 and fell as low as $3000.0 in Q3 2023.
- A 5-year average of $98000.0 and a median of $116500.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets tumbled 98.2% — and 2026, when it soared 285.29%.
- Year by year, Other Non-Current Assets stood at $103000.0 in 2022, then plunged by 97.09% to $3000.0 in 2023, then surged by 1033.33% to $34000.0 in 2024, then soared by 282.35% to $130000.0 in 2025, then rose by 0.77% to $131000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $131000.0, $130000.0, and $131000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 131,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 103,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | 180,000.00 |
| Mar 31, 2022 | 190,000.00 |
| Dec 31, 2021 | 61,000.00 |
| Dec 31, 2020 | 44,000.00 |
| Sep 30, 2020 | 109,000.00 |
| Jun 30, 2020 | 173,000.00 |
| Mar 31, 2020 | 233,000.00 |
| Dec 31, 2019 | 293,000.00 |
| Mar 31, 2015 | -155.87 Mn |
| Dec 31, 2013 | 164,882.97 |